ACE2 and lung disorder: Conversely, strategies focused in increasing ACE2 levels or activity such as administration of recombinant human ACE2 (rhACE2), have shown protective effects in CVD and pulmonary diseases (59, 60, 62) and have been suggested as a potential biological therapy against SARS-CoV-2 infection (63, 64).